Hysobrid 375 Tablet contains Sultamicillin tosilate 375 mg, a combination antibiotic comprising ampicillin and sulbactam in a prodrug form that enhances oral bioavailability. It is indicated for the treatment of various bacterial infections caused by susceptible organisms, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections. Sultamicillin exerts its antibacterial effect by inhibiting bacterial cell wall synthesis through the ampicillin component, while sulbactam acts as a beta-lactamase inhibitor, preventing the degradation of ampicillin by beta-lactamase-producing bacteria, thereby broadening the spectrum of activity. This dual action makes Hysobrid 375 effective against both beta-lactamase-producing and non-producing strains of bacteria. The tablet is administered orally, with dosage and duration dependent on the severity and type of infection, as well as patient-specific factors such as age, renal function, and clinical response. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and rash. Hypersensitivity reactions to penicillins should be carefully considered before prescribing. Hysobrid 375 should be used under medical supervision, ensuring appropriate use to minimize the development of antibiotic resistance.